Rebus Holdings Inc (RBSH)

[jwblue74]

Product Development of Adenosine Receptor Modulators

https://www.sec.gov/Archives/edgar/data/1421204/000161577417006918/s108227_10q.htm

Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation. High levels of adenosine in the tumor microenvironment inhibits immune response mediated through the A2A and A2B receptors. Adenosine also plays a role in non-malignant conditions where it is rapidly increased in response to inflammation, hypoxia, ischemia, or trauma. Adenosine released in this setting has been shown to have a protective effect and limits excessive inflammatory damage to tissues.

The adenosine receptor antagonists have broad applicability as a potential immuno-oncology (IO) therapeutic agent in multiple tumor types both as a single agent and in combination with other IO agents, in addition to traditional cytotoxic chemotherapy. We are actively seeking licensing opportunities and/or partners to further development our A2A, A2B and dual A2A/A2B receptor antagonists. Our current product development plan for adenosine receptor antagonists contemplates the following major initiatives:

License and/or partner to companies intending to further the develop the A2A, A2B and/or dual A2A/A2B receptor antagonists.

Further characterization of existing agents, specifically the A2B and dual A2A/A2B receptor antagonists, toward IND enabling studies and support ongoing licensing/partnership activities.

Conduct IND enabling studies.

Conduct clinical studies with one or more of the adenosine receptor antagonists.

Continue generating additional adenosine receptor antagonists to expand our portfolio.

The adenosine receptor agonists have applicability in a broad range of non-oncology conditions including inflammatory and autoimmune diseases and conditions. We are actively seeking licensing opportunities and/or partners to further development our A2A receptor agonists. Our current product development plan for adenosine receptor agonists contemplates the following major initiatives:

License and/or partner to companies with development expertise in the intended indication.

Further characterize existing agents to support licensing/partnership activities.

Continue generating additional adenosine receptor agonists to expand our portfolio.

$NSPX